Venus Medtech Stock Market Value
| VMTHF Stock | USD 0.42 0.15 55.56% |
| Symbol | Venus |
Venus Medtech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Venus Medtech's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Venus Medtech.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Venus Medtech on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Venus Medtech or generate 0.0% return on investment in Venus Medtech over 90 days. Venus Medtech is related to or competes with Avita Medical, BICO Group, Cellink AB, 3-D Matrix, Paxman AB, Jushi Holdings, and Molecular Partners. Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internati... More
Venus Medtech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Venus Medtech's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Venus Medtech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0802 | |||
| Maximum Drawdown | 10.0 |
Venus Medtech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Venus Medtech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Venus Medtech's standard deviation. In reality, there are many statistical measures that can use Venus Medtech historical prices to predict the future Venus Medtech's volatility.| Risk Adjusted Performance | 0.0835 | |||
| Jensen Alpha | 0.7841 | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.41) |
Venus Medtech February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0835 | |||
| Market Risk Adjusted Performance | (0.40) | |||
| Mean Deviation | 1.72 | |||
| Coefficient Of Variation | 1072.29 | |||
| Standard Deviation | 7.09 | |||
| Variance | 50.3 | |||
| Information Ratio | 0.0802 | |||
| Jensen Alpha | 0.7841 | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.41) | |||
| Maximum Drawdown | 10.0 | |||
| Skewness | 7.54 | |||
| Kurtosis | 59.61 |
Venus Medtech Backtested Returns
Venus Medtech appears to be out of control, given 3 months investment horizon. Venus Medtech owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0933, which indicates the firm had a 0.0933 % return per unit of risk over the last 3 months. By inspecting Venus Medtech's technical indicators, you can evaluate if the expected return of 0.66% is justified by implied risk. Please review Venus Medtech's Risk Adjusted Performance of 0.0835, variance of 50.3, and Coefficient Of Variation of 1072.29 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Venus Medtech holds a performance score of 7. The entity has a beta of -1.61, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Venus Medtech are expected to decrease by larger amounts. On the other hand, during market turmoil, Venus Medtech is expected to outperform it. Please check Venus Medtech's jensen alpha, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to make a quick decision on whether Venus Medtech's existing price patterns will revert.
Auto-correlation | -0.43 |
Modest reverse predictability
Venus Medtech has modest reverse predictability. Overlapping area represents the amount of predictability between Venus Medtech time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Venus Medtech price movement. The serial correlation of -0.43 indicates that just about 43.0% of current Venus Medtech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.43 | |
| Spearman Rank Test | -0.5 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Venus Pink Sheet
Venus Medtech financial ratios help investors to determine whether Venus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Venus with respect to the benefits of owning Venus Medtech security.